RA
BLFS icon

Royce & Associates’s BioLife Solutions BLFS Stock Holding History

Royce & Associates’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.6M Buy
623,875
+39,864
+7% +$932K 0.14% 239
2026
Q1 		$11.1M Buy
584,011
+166,921
+40% +$3.69M 0.11% 295
2025
Q4 		$10.1M Sell
417,090
-54,839
-12% -$1.43M 0.1% 299
2025
Q3 		$12M Sell
471,929
-49,876
-10% -$1.18M 0.12% 255
2025
Q2 		$11.2M Sell
521,805
-338,939
-39% -$7.64M 0.12% 256
2025
Q1 		$19.7M Buy
860,744
+83,462
+11% +$2.2M 0.21% 142
2024
Q4 		$20.2M Sell
777,282
-47,851
-6% -$1.19M 0.19% 159
2024
Q3 		$20.7M Sell
825,133
-87,519
-10% -$2.07M 0.19% 153
2024
Q2 		$19.6M Buy
912,652
+397,445
+77% +$7.71M 0.18% 157
2024
Q1 		$9.56M Sell
515,207
-356,396
-41% -$6.23M 0.09% 344
2023
Q4 		$14.2M Buy
871,603
+628,827
+259% +$8.02M 0.13% 212
2023
Q3 		$3.35M Buy
+242,776
New +$3.83M 0.03% 561
2022
Q4 		– Sell
-21,600
Closed -$491K – 915
2022
Q3 		$491K Sell
21,600
-200
-0.9% -$4.28K 0.01% 819
2022
Q2 		$301K Buy
+21,800
New +$320K ﹤0.01% 884
2022
Q1 		– Sell
-57,300
Closed -$2.14M – 964
2021
Q4 		$2.14M Sell
57,300
-129,856
-69% -$5.57M 0.02% 718
2021
Q3 		$7.92M Buy
187,156
+1,960
+1% +$94.4K 0.06% 481
2021
Q2 		$8.24M Sell
185,196
-116,300
-39% -$4.1M 0.06% 480
2021
Q1 		$10.9M Sell
301,496
-543,620
-64% -$21.5M 0.07% 419
2020
Q4 		$33.7M Hold
845,116
– – 0.28% 81
2020
Q3 		$24.5M Buy
845,116
+165,500
+24% +$3.57M 0.26% 91
2020
Q2 		$11.1M Buy
679,616
+198,900
+41% +$2.74M 0.12% 235
2020
Q1 		$4.57M Buy
480,716
+260,000
+118% +$3.57M 0.06% 399
2019
Q4 		$3.57M Buy
220,716
+24,061
+12% +$391K 0.03% 570
2019
Q3 		$3.27M Buy
196,655
+10,000
+5% +$188K 0.03% 585
2019
Q2 		$3.16M Buy
+186,655
New +$3.25M 0.03% 612

Other funds holding BLFS

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Royce & Associates's BLFS Position: Q2 2026 in Review

Royce & Associates increased its BioLife Solutions (BLFS) stake by 6.8% in Q2 2026, buying an estimated $932K and bringing the position to 623,875 shares worth $17.6M. The position accounts for 0.14% of the portfolio, ranked #239.

Royce & Associates first reported a position in BLFS in Q2 2019 and has held it in 25 quarters since. The position peaked at $33.7M in Q4 2020. 216 funds tracked by Wall St. Rank hold BLFS as of Q2 2026.

  • Royce & Associates held 623,875 shares of BioLife Solutions worth $17.6M as of Q2 2026.
  • Royce & Associates bought 39,864 BioLife Solutions shares in Q2 2026, an estimated $932K.
  • BioLife Solutions made up 0.14% of Royce & Associates's portfolio in Q2 2026, its #239 holding.
  • Royce & Associates first reported a position in BioLife Solutions in Q2 2019 and has held it in 25 quarters since.
  • Royce & Associates's BioLife Solutions position peaked at $33.7M in Q4 2020.
  • 216 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.